What is pathophysiology of Lung cancer?

['ⵙⵎⴷ ⵜⴰⴱⵔⴰⵜ ⴰⴷ']

ⵎⴰⵜⵜⴰ ⵜⴰⴷⵉⵎⴰⵡⴰⵏⵜ ⵏ ⵓⴱⴰⵜⵓ ⵏ ⵍⴽⵏⵚⵉⵔ ⵏ ⵓⵖⵢⵓⵍ?

ⴷⴰ ⵉⵜⵜⴰⵡⵢ ⵓⴱⴰⵜⵓⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉ ⵏ ⵓⴽⵕⵥⵎ ⵏ ⵓⵖⵢⵓⵍ ⵙ ⵉⵙⵏⴼⴰⵍ ⴳ ⵜⵎⴳⴳⵉⵜⵉⵏ ⴷ ⵉⵎⴰⵙⵙⵏ ⵏ ⵜⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉⵜ ⵜⴰⴳⴰⵎⴰⵏⵜ ⵏⵏⴰ ⵉⵜⵜⵉⵍⵉⵏ ⴳ ⵓⴱⵓⵖⵍⵓ ⴷ ⵓⴱⵓⵖⵍⵓ ⵏ ⵓⴽⵕⵥⵎ ⵏ ⵓⵖⵢⵓⵍ.

ⵉⴳⴰ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵓⵖⵢⵓⵍ ⵢⴰⵜ ⵜⵎⴰⴹⵓⵏⵜ ⵉⴳⴳⵓⵜⵏ ⵏⵏⴰ ⵉⵜⵜⵓⵙⴽⴰⵔⵏ ⵙ ⵜⵎⵔⵏⵉⵡⵜ ⵓⵔ ⵉⵜⵜⵓⵃⴹⴰⵏ ⴷ ⵓⴱⵟⵟⵓ ⵏ ⵜⵖⵔⴰⵙⵉⵏ ⵓⵔ ⵉⵍⵉⵏ ⵉⵃⵟⵟⵓⵏ ⴳ ⵓⵖⵢⵓⵍ.

ⵉⵖⵢ ⴰⴷ ⵙⴽⵔⵏ ⵉⵖⵔⴰⴱⴰⵏ ⴰⴷ ⵜⵉⴽⵍⵉⵡⵉⵏ ⴷ ⴰⴷ ⵙⵙⴼⵙⵉⵏ ⵖⵔ ⵜⴼⵓⵍⵉⵏ ⵢⴰⴹⵏⵉⵏ ⵏ ⵜⴼⴳⴳⴰ, ⵏⵏⴰ ⵉⵙⵙⵉⵔⵉⵡⵏ ⵙ ⴽⵉⴳⴰⵏ ⵏ ⵜⵎⴰⵜⴰⵔⵉⵏ ⴷ ⵜⵎⵓⴽⵔⵉⵙⵉⵏ.

ⴷⴰ ⵉⵜⵜⵓⵙⵎⵓⵏ ⵓⴱⴰⵜⵓⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉ ⵏ ⵓⴽⵕⵥⵎ ⵏ ⵓⵖⵢⵓⵍ ⴳ ⴽⵉⴳⴰⵏ ⵏ ⵉⵎⵙⴽⴰⵔⵏ, ⴳ ⵍⵍⴰⵏ ⵉⵎⵓⵜⵜⵉⵢⵏ ⵉⵊⵉⵏⵉⵜⵏ, ⵉⵎⵙⴽⴰⵔⵏ ⵏ ⵜⵡⵏⵏⴰⴹⵜ, ⴷ ⵡⴰⵏⴰⵡⵏ ⵏ ⵜⵓⴷⵔⵜ.

ⵉⵖⵢ ⴰⴷ ⵢⵉⵍⵉ ⵓⵙⵏⴼⵍ ⴰⵊⵉⵏⵉ ⴳ ⵓⵖⵢⴰⵢ ⵏ ⵜⵖⵔⴰⵙⵉⵏ ⵏ ⵉⴼⵙⴰⵏ, ⵏⵏⴰ ⵉⵜⵜⴰⵡⵉⵏ ⵙ ⵜⴳⵎⵉ ⴷ ⵓⴱⵟⵟⵓ ⵏ ⵜⵖⵔⴰⵙⵉⵏ ⵓⵔ ⵉⵜⵜⵓⵙⵏⴱⴰⴹⵏ.

ⵉⵖⵢ ⴰⴷ ⵜⵜⵓⵙⵏⴼⵍⵏ ⵉⵙⵏⴼⵍⵏ ⴰⴷ ⵙ ⵜⴰⴽⴽⵓⵙⵜ ⵏⵖⴷ ⵙ ⵜⵓⵙⵙⵏⴰ, ⴷ ⵉⵖⵢ ⴰⴷ ⵜⵜⵓⵙⴽⵔⵏ ⵙ ⵓⵙⴼⵙⵔ ⵏ ⵉⵎⵖⴰⵢⵏ ⵏ ⵍⴽⴰⵔⵙⵉⵏ, ⵣⵓⵏⴷ ⴰⵣⵣⴰⵎⴰⵏ ⵏ ⵓⵙⵙⵉⴽⵍ, ⵕⴰⴷⵓⵏ, ⴰⵙⴱⵉⵙⵜⵓⵙ, ⴷ ⵓⵙⵏⵓⵣⵔ ⵏ ⵓⵣⵡⵓ.

ⵉⵖⵢ ⴰⴷ ⵉⵜⵜⵓⵙⵎⵢⴰⵏⴰⵡ ⵓⴽⵕⵥⵎ ⵏ ⵓⵖⵢⵓⵍ ⵙ ⵙⵉⵏ ⵡⴰⵏⴰⵡⵏ ⵉⵎⵇⵔⴰⵏⵏ: ⵓⴽⵕⵥⵎ ⵏ ⵓⵖⵢⵓⵍ ⵏ ⵜⵖⵔⴰⵙⵜ ⵜⴰⵎⵥⵥⵢⴰⵏⵜ (SCLC) ⴷ ⵓⴽⵕⵥⵎ ⵏ ⵓⵖⵢⵓⵍ ⵓⵔ ⵉⴳⵉⵏ ⵏ ⵜⵖⵔⴰⵙⵜ ⵜⴰⵎⵥⵥⵢⴰⵏⵜ (NSCLC). ⴷⴰ ⵉⵜⵜⵓⵙⵎⵢⴰⵏⴰⵡ NSCLC ⵙ ⴽⵕⴰⴹ ⵡⴰⵏⴰⵡⵏ ⵉⵎⵥⵥⵢⴰⵏⵏ: ⴰⴷⵢⵏⵓⴽⴰⵔⵙⵉⵏⵓⵎⴰ, ⵓⴽⵕⵥⵎ ⵏ ⵜⵖⵔⴰⵙⵜ ⵜⴰⴱⵍⴽⵉⵎⵜ, ⴷ ⵓⴽⵕⵥⵎ ⵏ ⵜⵖⵔⴰⵙⵜ ⵜⴰⵎⵇⵇⵔⴰⵏⵜ.

ⵉⵖⵢ ⴰⴷ ⵉⵎⵣⴰⵔⴰⵢ ⵓⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵡⴰⵏⴰⵡⵏ ⴰⴷ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵓⵖⵢⵉⵎ, ⴰⵛⴽⵓ ⵖⵓⵔⵙⵏ ⵉⵎⵓⵜⵜⵉⵢⵏ ⵉⵊⵉⵏⵉⵜⵏ ⵉⵎⵣⴰⵔⴰⵢⵏ ⴷ ⴰⵔ ⵜⵜⵔⴰⵔⴰⵏ ⵙ ⵢⴰⵜ ⵜⵖⴰⵔⴰⵙⵜ ⵉⵎⵣⴰⵔⴰⵢⵏ ⵉ ⵓⵙⵎⴽⵍ.

ⴷⴰ ⵉⵜⵜⴰⵎⵓ ⵓⴱⴰⵜⵓⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉ ⵏ ⵓⴽⵕⵥⵎ ⵏ ⵓⵖⵢⵓⵍ ⴳ ⵓⵎⵔⴰⵔⴰ ⵏ ⵜⵡⵓⵔⵉ ⴳⵔ ⵜⵖⵔⴰⵙⵉⵏ ⵏ ⵓⴽⵕⵥⵎ ⴷ ⵉⵎⵟⵟⴰⵢⵏ ⵏ ⵓⵡⵏⴰⴹ, ⴳ ⵉⵍⵍⴰ ⵓⵏⴳⵔⴰⵡ ⵏ ⵓⵏⴳⵉ.

ⵉⵖⵢ ⴰⴷ ⵙⵙⵓⵔⴼⵏ ⵉⴼⵔⴰⵢⵏ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⴰⵏⴳⵔⴰⵡ ⵏ ⵓⴼⵔⴰⴳ, ⴰⵢⴰ ⵉⵜⵜⴰⴷⵊⴰ ⴰⵙⵏ ⴰⴷ ⵙⵙⴱⵓⵖⵍⵓⵏ ⴷ ⴰⴷ ⵙⵙⴱⵉⴷⴷⵏ ⴱⵍⴰ ⵜⵉⴹⴰⴼ.

ⵙ ⵓⵙⵎⵓⵏ, ⵉⵖⵢ ⴰⴷ ⵉⵙⴱⵓⵖⵍⵓ ⵓⵎⵏⴰⴹ ⴰⵎⵥⵥⵢⴰⵏ ⵏ ⵓⴳⵕⴹ ⵜⵉⴳⵎⵉ ⵏ ⵓⴳⵕⴹ ⴷ ⵓⵙⵙⴼⵙⵉ ⵙ ⵜⵉⴽⴽⵉ ⵏ ⵢⴰⵏ ⵓⵎⵏⴰⴹ ⴰⵏⵏⴰⵍ ⵉ ⵜⵖⵔⴰⵙⵉⵏ ⵏ ⵍⴽⵓⵏⵚⵉⵕ.

ⵜⴳⴰ ⵜⴱⴰⵜⵓⴼⵉⵣⵉⵓⵍⵓⵊⵉⵜ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵓⵖⵢⵓⵍ ⵢⴰⵜ ⵜⵎⴳⴳⵉⵜ ⵉⵔⵡⵉⵏ ⴷ ⵜⴰⴷⵉⵏⴰⵎⵉⵜ, ⴰⵔ ⵙⵡⵓⵔⵉⵏ ⵉⵎⵔⵣⵓⵜⵏ ⵙ ⵓⵙⵎⵓⵜⵜⴳ ⴰⴼⴰⴷ ⴰⴷ ⵔⵎⵙⵏ ⵙ ⵜⵖⴰⵔⴰⵙⵜ ⵢⵓⴼⵏ ⵉⵎⴰⵙⵙⵏ ⵏ ⵓⴷⵔⴰⵔ ⴰⴼⴰⴷ ⴰⴷ ⵙⴱⵓⵖⵍⵓⵏ ⵜⵉⵙⵉⵊⵊⵉⵜⵉⵏ ⵉⵕⵡⵉⵏ ⵓⴳⴳⴰⵔ ⴷ ⴰⴷ ⵙⴱⵓⵖⵍⵓⵏ ⵜⵉⵢⴰⴼⵓⵜⵉⵏ ⵏ ⵉⵎⵓⴹⴰⵏ.

['ⵉⵙⵓⵎⴰⵔ']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.

Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.

Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.

Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .

Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .

Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.

['ⴰⵙⴱⴷⵉⴷ: ⴰⵎⵙⵏⵉⵊⵊⵉ']

['ⴰⵙⵉⵜ ⴰⴷ ⵉⵜⵜⵓⴼⴽⴰ ⵖⴰⵙ ⵉ ⵓⵡⵜⵜⴰⵙ ⵏ ⵓⵙⵙⵍⵎⴷ ⴷ ⵓⵙⵏⵖⵎⵙ, ⵓⵔ ⵉⴳⵉ ⴰⵙⴼⴽ ⵏ ⵓⵎⵛⴰⵡⴰⵕ ⵏ ⵓⴷⵓⵙⵜⵓⵔ ⵏⵖⴷ ⵜⵡⵓⵔⵉⵡⵉⵏ ⵜⵉⵣⵣⵓⵍⴰⵏⵉⵏ.']

['ⵓⵔ ⵉⵇⵇⵉⵏ ⴰⴷ ⵉⵜⵜⵓⵙⵎⵔⵙ ⵓⵎⵍⴰⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵓⵙⵎⵔⵙ ⵏ ⵓⵙⵎⵉⴳⵍ ⵏⵖⴷ ⵓⵙⵓⵊⵊⵉ ⵏ ⵜⵎⵓⴽⵔⵉⵙⵜ ⵏ ⵜⴷⵓⵙⵉ ⵏⵖⴷ ⵜⵎⴰⴹⵓⵏⵜ, ⴷ ⵡⵉⵏⵏⴰ ⵉⵔⴰⵏ ⴰⵙⵇⵇⵙⵉ ⴰⵎⵙⵏⵉⵊⵊⵉ ⴰⵡⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⵉⵇⵇⴰⵏ ⴰⴷ ⵙⴰⵡⵍⵏ ⴷ ⵓⵎⵙⵏⵉⵊⵊⵉ ⵉⵜⵜⵓⵥⵍⴰⵢⵏ.']

['ⵙ ⵡⴰⵍⵍⵍⵉ ⵉⵜⵜⵓⵢⴰⵏⵏⴰ, ⵜⴰⵔⴰⵜⵙⴰ ⵏ ⵓⵏⵢⵓⵔⴰⵍ ⵏⵏⴰ ⵉⵜⵜⴰⴽⴽⴰⵏ ⵜⵉⵎⵔⴰⵔⵓⵜⵉⵏ ⵉ ⵉⵙⵇⵙⵉⵜⵏ, ⵓⵔ ⴷⴰ ⵜⵜⵉⵍⵉ ⴰⴽⴽⵡ ⵜⵓⵙⴷⵉⴷⵜ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵓⵡⵏⵖ ⵏ ⵓⵟⵟⵓⵏ. ⵙ ⵓⵎⴷⵢⴰ, ⵓⵟⵟⵓⵏ ⵏ ⵎⴷⴷⵏ ⵉⵜⵜⵓⵙⵏⴼⴰⵍⵏ ⵖⴼ ⵜⵎⴰⴹⵓⵏⵜ ⵉⵥⵍⵉⵏ.']

['ⵚⵓⴰⵍ ⵙⵓⵍ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⵏⵏⴽ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⵙⵙⵉⵡⵍ ⵏ ⵜⴷⵓⵙⵉ ⵢⴰⴹⵏ ⵉⵇⴱⵍⵏ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ. ⵓⵔ ⴰⴽⴽⵡ ⴰⴷ ⵜⵙⵙⴼⵍⴷ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⴰⵣⵣⵓⵍⴰⵏ ⵏⵖⴷ ⴰⴷ ⵜⵣⴰⵢⴷ ⴳ ⵓⵙⵓⵜⴳ ⵏⵏⵙ ⴰⵛⴽⵓ ⵏⵜⵜⴰⵜ ⴰⵢⴷ ⵜⵙⵙⵖⵔⴷ ⴳ ⵓⵙⵉⵜ ⴰⴷ. ⵎⴽ ⵜⵓⵔⴷⴰ ⴰⴷ ⵖⵓⵔⴽ ⵉⵍⵍⴰ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ ⵉⵣⵣⴳⵔⵏ, ⵙⵎⴷ 911 ⵏⵖⴷ ⴰⴷ ⴷⵉⴷⵜ ⵜⴰⵍⵙ ⴷⴰⵔ ⵜⴰⴷⴰⵍⴰ ⵏ ⵓⵣⵣⵔⴰⵢ ⵏ ⵣⵉⴽⴽ. ⵓⵔ ⵜⵍⵍⴰ ⵜⵓⵇⵇⵏⴰ ⵏ ⵓⵊⵉⵊⵊⵉ ⴷ ⵓⵎⵏⵉⴳ ⵙ ⵓⵙⵉⵜ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ. ⵓⵔ ⴷⴰ ⵜⵙⴽⴰⵔ ⴱⵢⵓⵎⵉⴷⵍⵉⴱ ⵏⵖⴷ ⵉⵎⵙⵡⵓⵔⵉⵏ ⵏⵏⵙ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⴷⵔⴰⵡ ⴳ ⵓⵙⵉⵜ ⴰⴷ ⴽⵔⴰ ⵏ ⵓⵙⵎⴷⵢⴰ, ⵙ ⵡⴰⵡⴰⵍ ⵏⵖⴷ ⵙ ⵓⵙⵏⵓⵎⵍ, ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵍⵍⴰⵏ ⴳ ⵓⴷⵖⴰⵔ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ.']

['ⴰⵙⴱⴰⴷⵓ: ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⴼⵓⵙ']

['ⴰⵛⵔⵓⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ']

['ⵎⴽ ⵜⵛⵛⵉⵖⴰⵍⴷ ⵙ ⵜⵛⵛⵉⵢⵜ ⵎⴰⵙⴷ ⴽⵔⴰ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ ⵏⵏⴰ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵏⵖⴷ ⵜⵉⵙⵏⵙⵉ ⵏⵏⵓⵏ ⴷⴰ ⵉⴽⵛⵎⵏ ⴳ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵣⵔⴼ ⵏⵏⵓⵏ, ⵜⵣⵎⵔⴷ ⴰⴷ ⵜⴰⵍⵙⴷ (ⵏⵖ ⴰⵎⴷⵢⴰⵣ ⵏⵏⴽ) ⴰⴷ ⵜⵙⵏⵎⵍⴷ ⵉ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵙ ⵓⵙⵓⵜⵔ ⵏ ⵓⵙⵙⵉⴷⴼ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ, ⵏⵖⴷ ⴰⴷ ⵜⴱⴷⴷⴷ ⵜⵉⵍⵉⵜ ⵏⵏⵙⵏ.']

['ⵉⵏⴰⵓⴰⵏ ⴰⵂⴰⵏ ⴰⴾⵜⴰⴱ ⵙ ⴰⵍⴾⵉⵜⵜⴰⴱ ⵙ ⵎⵢⵍ (ⵉⴾⵉⴰⴷ ⵙ ⴰⴾⵜⴰⴱ "ⵎⵢⵍ" ⵉ ⵎⵢⵍ)']

['DMCA ⵜⵙⵙⵓⵜⵔ ⴰⵙⵎⵉⵙⵉ ⵏⵏⴽ ⵏ ⵓⵎⴳⴰⵍ ⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵉⴽⵛⵎ ⴳ ⵓⵙⵎⵎⴰⵍ ⴰⴷ: (1) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵡⵓⵔⵉ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵏⵏⴰ ⵉⴳⴰⵏ ⴰⵙⵏⵜⵍ ⵏ ⵓⵎⴳⴰⵍ; (2) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵓⵎⴰⵢⵜ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⴷ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵅⵚⵚⴰⵏ ⴰⴼⴰⴷ ⴰⴷ ⵏⴰⴼ ⵜⵓⵎⴰⵢⵜ; (3) ⵉⵏⵖⵎⵉⵙⵏ ⵏ ⵓⵎⵢⴰⵡⴰⴹ ⴰⴽⴷⴽ, ⴳ ⵉⵍⵍⴰ ⵡⴰⵏⵙⴰ ⵏⵏⴽ, ⵓⵟⵟⵓⵏ ⵏ ⵜⵉⵍⵉⴼⵓⵏ ⴷ ⵡⴰⵏⵙⴰ ⵏ ⵓⵍⵉⴽⵜⵕⵓⵏ; (4) ⴰⵙⵉⵡⴹ ⵏⵏⴽ ⵎⴰⵙ ⴷⴰⵔⴽ ⵜⴰⵍⵍⵉⵍⵜ ⵉⵖⵓⴷⴰⵏ ⵏ ⵓⵙⵏⴽⴷ ⵎⴰⵙ ⵜⵓⵎⴰⵢⵜ ⵙ ⵜⵖⴰⵔⴰⵙⵜ ⵏⵏⴰ ⵜⵙⵙⵔⴳⴰⵍ ⵓⵔ ⵜⴽⴽⵉ ⵜⵓⵔⴰⴳⵜ ⵙⴳ ⵖⵓⵔ ⵡⴰⵏⵏⴰ ⵉⵟⵟⴰⴼⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ, ⵏⵖⴷ ⴰⵎⴷⵢⴰⵣ ⵏⵏⵙ, ⵏⵖⴷ ⵙ ⵓⵙⵡⵓⵔⵉ ⵏ ⴽⵔⴰ ⵏ ⵓⵙⵍⴳⵏ; ']

['(5) ⴰⵙⵉⵙⵙⵉⴾⵉ ⵏⵢⵜ, ⵉⴾⴼⴰⵏ ⵙ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⵜⵉⴷⵉⵜ, ⴰⵙ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵏⴰⵙⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⴷ ⴰⵙ ⵉⵍⴰ ⴰⴾⴰⵉⴰⴷ ⵉ ⴰⵙⵓⵋ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵜⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉ ⴰⵋⵋⴰⵏⵢⵏ']

['ⴷ (6) ⴰⴾⴰⵔⵓⵙ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵎⵢⵗ ⵓⴰ ⵉⵋⵋⴰⵏ ⵙ ⵢⵎⵢⵍ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ']

['ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵙⴰⴾⵏⵢ ⵏ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⴰⵋⵋⵓⵜⵏⵢⵏ ⴰⴷⴷⵓⴱⴰⵜ ⴰⴷ ⵢⵈⵈⵉⵍ ⴰⵙⵉⵓⴰⴷ ⵏ ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏⵢⵜ']

['ⴰⵎⵢⴰⵡⴰⴹ']

['ⵙⵓⴾⵢⵍ ⵉⵢⵎⴰⵍ ⵉⵢⵎⴰ ⵙ ⴽⴰⴾⴰⵎⴰⵍ ⴰⵙⵉⵙⵜⴰⵏ/ⴰⵙⵓⵋ']

What is pathophysiology of lung cancer?

The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.

Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.

These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.

The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.

Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.

These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.

Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.

The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.

Cancer cells can evade the immune system, allowing them to grow and spread unchecked.

Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.

The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.

['ⴰⵜⵜⴰⵢⵏ']

['ⴷⴰ ⵉⵙⵙⵎⵔⴰⵙ ⴱⵢⵓ ⵎⵉⴷⵍⵍⵉⴱ ⵉⵎⴰⵙⵙⵏ ⵏ ⵓⵙⵉⴳⴳⵍ ⵉⵎⵉⴽⵙⵉⵍⵏ (ⴰⵍⴳⵓⵔⵉⵜⵎ ⵏ ⵓⵍⵎⵎⵓⴷ ⵏ ⵉⵎⵉⵙ) ⵉ ⵓⵙⵓⴼⵖ ⵏ ⵉⵎⵣⵉⵏⵏ ⵏ ⵉⵙⵇⵙⵉⵜⵏ ⴷ ⵜⵎⵔⴰⵔⵓⵜⵉⵏ.']

['ⴷⴰ ⵏⵙⵙⵏⵜⵉ ⵙ 35 ⵎⵍⵢⵓⵏ ⵏ ⵜⵥⵕⵉⴳⵉⵏ ⵏ ⵜⵙⵏⵉⵊⵊⵉⵜ ⵜⴰⴱⵢⵓⵎⵉⴷⵉⴽⵜ ⵏ ⴱⴰⴱⵎⵉⴷ/ⵎⵉⴷⵍⵉⵏ. ⵓⵍⴰ ⴰⵡⴷ ⵜⵉⴼⵔⴽⵉⵏ ⵏ ⵡⵉⴱ ⵏ ⵔⴰⴼⵉⵏⴷⵡⵉⴱ.']

['ⴰⵜ-ⵓ-ⴰⵗ "ⴰⵍⵓⴰⵈⴰⵏ" ⴰⴷ "ⴰⴾⴼⴰⵣ"']